Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.60 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5553943 | 0.89 | HRH3 (0.57) | HRH3CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5553173 | 0.84 | POLB (0.50) | HRH3CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5549869 | 0.82 | MEN1 (0.52) | HRH3CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5554012 | 0.82 | CHRNB2 (0.46) | HRH3CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5553171 | 0.82 | CHRNB2 (0.48) | HRH3CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5550048 | 0.81 | CHRNB2 (0.54) | HRH3CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5555178 | 0.78 | CHRNB2 (0.50) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL5553142 | 0.78 | HRH3 (0.51) | HRH3CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5550038 | 0.77 | HRH3 (0.63) | HRH3CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5553038 | 0.77 | CHRNB2 (0.49) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756058-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-02-28 | — | — | EP | claimed |
| WO-2005105744-A1 | HISTAMINE-3 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. | 2005-11-10 | — | — | WO | claimed |
| US-20050245543-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2005-11-03 | — | — | US | claimed |
| US-20050245543-A1 | Histamine-3 receptor antagonists | PFIZER INC | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245543-A1 | Histamine-3 receptor antagonists | HRH3, HRH4, HRH2 | HRH3 1/4885CHRNB2 434/4885CHRNB4 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.